White paper on microbial anti-cancer therapy and prevention.

White paper on microbial anti-cancer therapy and prevention.
复制标题

DOI:
10.1186/s40425-018-0381-3
复制
发表时间:
2018-08-06
影响因子:
10.9
通讯作者:
McFadden G
McFadden G
中科院分区:
医学2区
文献类型:
--
作者:
Forbes NS;Coffin RS;Deng L;Evgin L;Fiering S;Giacalone M;Gravekamp C;Gulley JL;Gunn H;Hoffman RM;Kaur B;Liu K;Lyerly HK;Marciscano AE;Moradian E;Ruppel S;Saltzman DA;Tattersall PJ;Thorne S;Vile RG;Zhang HH;Zhou S;McFadden G

文献摘要

参考文献

被引文献

相似文献

在这份白色白皮书中,我们讨论了微生物癌症治疗的现状。这篇论文来自2017年夏天在美国国家癌症研究所举行的一次会议(“基于微生物的癌症治疗”)。在这里,我们将“微生物疗法”定义为包括溶瘤病毒疗法和细菌抗癌疗法。这两个领域都利用肿瘤特异性感染性微生物来治疗癌症,具有相似的作用机制,并且面临着类似的商业化挑战。我们设计这篇论文是为了使这个不断发展的微生物治疗领域成为核心,并增加它和相关领域研究人员之间的互动。本文作者包括该领域的许多主要研究人员。在本文中,我们讨论了微生物治疗的潜力,现状和机会,以及迄今为止尝试的策略和需要解决的重要问题。我们认为将产生最大影响的主要领域是免疫刺激,疗效控制,交付控制和安全性。这一领域治疗目前难治性癌症的潜力令人兴奋。这些疗法之所以具有很大的潜力,是因为它们利用了其他生物或小分子药物难以实现的独特作用机制。通过更好地理解和控制这些机制,我们将创造新的疗法,成为癌症护理的组成部分。
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial Therapy’ to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.
DOI: 10.1080/2162402x.2017.1398875
发表时间: 2018
期刊: Oncoimmunology
影响因子: 7.2
作者:
Bazett M;Costa AM;Bosiljcic M;Anderson RM;Alexander MP;Wong SWY;Dhanji S;Chen JM;Pankovich J;Lam S;Sutcliffe S;Gunn H;Kalyan S;Mullins DW
通讯作者: Mullins DW
DOI: 10.3322/caac.21398
发表时间: 2017-07-08
期刊: CA: a cancer journal for clinicians
影响因子: --
作者:
Bhatt AP;Redinbo MR;Bultman SJ
通讯作者: Bultman SJ
DOI: 10.1038/nrmicro1927
发表时间: 2008-07
期刊: Nature reviews. Microbiology
影响因子: --
作者:
通讯作者: --
DOI: 10.4049/jimmunol.0903231
发表时间: 2010-08-15
影响因子: 4.4
作者:
Bourquin, Carole;von der Borch, Philip;Endres, Stefan
通讯作者: Endres, Stefan
DOI: 10.1073/pnas.0406242101
发表时间: 2004-10-19
影响因子: 11.1
作者:
Agrawal, N;Bettegowda, C;Vogelstein, B
通讯作者: Vogelstein, B